Analyst Reco. Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Real-time Estimate Cboe BZX Other stock markets 03:04:51 2024-04-29 pm EDT			5-day change	1st Jan Change
0.711 ^USD	+3.04%		+1.85%	+38.51%

Apr. 01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT
Mar. 29	Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	Apr. 01	MT
Goldman Sachs Cuts Price Target on Atara Biotherapeutics to $0.50 From $3, Maintains Sell Rating	Nov. 10	MT
Evercore ISI Downgrades Atara Biotherapeutics to In Line From Outperform	Nov. 09	MT
HC Wainwright Downgrades Atara Biotherapeutics to Neutral From Buy	Nov. 09	MT
Mizuho Securities Downgrades Atara Biotherapeutics to Neutral From Buy, Slashes Price Target to $1 From $31	Nov. 09	MT
Citigroup Adjusts Atara Biotherapeutics Price Target to $1.40 From $2, Maintains Sell Rating	23-08-21	MT
HC Wainwright Adjusts Atara Biotherapeutics Price Target to $28 From $27, Maintains Buy Rating	23-06-14	MT
Canaccord Genuity Adjusts Price Target on Atara Biotherapeutics to $20 From $50, Maintains Buy Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on Atara Biotherapeutics to $27 From $29, Maintains Buy Rating	23-02-09	MT
Mizuho Securities Reiterates Atara Biotherapeutics at Buy With $31 Price Target	23-02-07	MT
EF Hutton Initiates Atara Biotherapeutics at Buy With $25 Price Target	23-01-05	MT
Mizuho Securities Cuts Price Target on Atara Biotherapeutics to $31 From $39, Keeps Buy Rating	22-08-16	MT
Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $3 From $4, Keeps Sell Rating	22-08-09	MT
Citigroup Downgrades Atara Biotherapeutics to Sell From Neutral; Price Target is $3	22-07-20	MT
Stifel Cuts Atara Biotherapeutics to Hold From Buy, Price Target to $5 From $16	22-07-13	MT
JPMorgan Downgrades Atara Biotherapeutics to Neutral From Overweight; Price Target is $10	22-07-13	MT
Goldman Sachs Adjusts Atara Biotherapeutics' Price Target to $4 from $5, Keeps Sell Rating	22-05-24	MT
HC Wainwright Adjusts Atara Biotherapeutics' Price Target to $29 from $31, Keeps Buy Rating	22-05-23	MT
Citigroup Downgrades Atara Biotherapeutics to Neutral From Buy, Sets $8 Price Target	22-05-09	MT
Stifel Adjusts Price Target for Atara Biotherapeutics to $18 From $20, Maintains Buy Rating	22-05-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Analyst Reco.

Filters